Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; proven medical device leader with more than 30 years of experience scaling commercial healthcare businesses MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of...

Q4 GAAP revenue of $104.5 million increased 317.7% year-over-year, driven by recently closed M&A transactions On a pro forma basis, Q4 same store sales increased 22% year-over-year and wholesale revenue increased 55% year-over-year; excluding Minnesota, same store sales increased 11.3% year-over-year Announced the pending acquisitions of Eaze, Schwazze, and PharmaCann retail assets in Colorado, and MOU for the acquisition of Hawthorne, all of which are expected to close in the first half of 2026 Company closed Q4 with $122.5 million in cash; expects to remain acquisitive MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its fourth fiscal quarter ended December 31, 2025. Key financial results are presented below in summary...

OTTAWA, Ontario, March 17, 2026 (GLOBE NEWSWIRE) — Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three and twelve-month periods ended December 31, 2025. All amounts are in Canadian dollars and reported under IFRS® Accounting Standards unless otherwise noted. “Telesat made strong progress on multiple fronts in 2025,” commented Dan Goldberg, Telesat’s President and CEO. “The development of the Telesat Lightspeed constellation – the satellites, associated software, user terminals, and landing stations – continues to move forward at a rapid pace. We’re seeing strong interest in Telesat Lightspeed from customers across our target market segments, with demand from government users for defence and sovereignty requirements being particularly...

Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly announced unblinded safety data from MRT-8102 SAD/MAD cohorts continue to support favorable safety/tolerability profile and wide therapeutic window Company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with elevated CVD-risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim data from the Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide showing 100% PSA response rate in metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations Phase...

SHANGHAI, China, March 17, 2026 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsNet revenue increased by 8.6% year-over-year (“Y-o-Y”) to RMB2,921.7 million (US$417.8 million) in the fourth quarter of 2025 (4Q2024: RMB2,690.7 million). Net loss1 was RMB462.8 million (US$66.2 million) in the fourth quarter of 2025 (4Q2024: RMB173.4 million). Net loss margin was 15.8% in the fourth quarter of 2025 (4Q2024: 6.5%). Adjusted EBITDA (non-GAAP) increased by 5.2% Y-o-Y to RMB1,365.6 million (US$195.3 million) in the fourth quarter of 2025 (4Q2024: RMB1,297.7...

– Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 – – Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for the Treatment of WHIM Syndrome in the European Union – – Balance Sheet Provides Cash Runway through 2028 – BOSTON, March 17, 2026 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. “Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with rare blood diseases,” said Adam Craig, M.D., Ph.D., Executive Chairman...

A total of 2,015 hotels, or 224,423 hotel rooms, in operation as of December 31, 2025. Net revenues for the fourth quarter of 2025 increased by 33.8% to RMB2,788 million (US$399 million), compared with RMB2,084 million for the same period of 2024. Net revenues for the full year of 2025 increased by 35.1% to RMB9,790 million (US$1,400 million), compared with RMB7,248 million for the full year of 2024.Net income for the fourth quarter of 2025 increased by 44.7% to RMB478 million (US$68 million), compared with RMB331 million for the same period of 2024. Net income for the full year of 2025 increased by 27.4% to RMB1,621 million (US$232 million), compared with RMB1,273 million for the full year of 2024.Adjusted net income (non-GAAP)1 for the fourth quarter of 2025 increased by 48.0% to RMB493 million (US$71 million), compared with RMB333...

HONG KONG, March 17, 2026 (GLOBE NEWSWIRE) — Mongolian Mining Corporation (“MMC” or the “Company”, and together with its subsidiaries, the “Group”; stock code: 975), the largest producer and exporter of washed coking coal products in Mongolia, today announced its annual results for the year ended 31 December 2025 (“FY2025” or the “Year”). The Group generated a total revenue of USD823.4 million in FY2025 (FY2024: USD1,039.9 million), of which USD792.1 million (FY2024: USD1,039.9 million) was generated by its coking (metallurgical) coal operations and USD31.3 million (FY2024: Nil) was generated by its gold and metals operations. The Group sold a total of 10.1 million tonnes (“Mt”) of coal products in FY2025, comprising of 4.9 Mt washed hard coking coal, 0.5 Mt washed semi-soft coking coal and 2.9 Mt of washed mid-ash semi-hard coking...

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) — Bakkt, Inc. (“Bakkt” or the “Company”) (NYSE:BKKT) today released a shareholder letter from Chief Executive Officer Akshay Naheta and reported its financial results for the full year ended December 31, 2025. The Company will discuss its results and 2026 strategic priorities at its Investor Day on March 17, 2026. To our Shareholders: Dear Fellow Shareholders, I am writing to you for the first time as CEO of Bakkt. When I joined the company, it was clear that significant rebuilding was required. Bakkt possessed something rare — a deep regulatory foundation and institutional pedigree rooted in its origins within Intercontinental Exchange — but the company itself had accumulated complexity over time. Strategy had become fragmented, resources were spread across non-core activities, and the...

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) — Bakkt, Inc. (“Bakkt” or the “Company”) (NYSE:BKKT) today released a shareholder letter from Chief Executive Officer Akshay Naheta and reported its financial results for the full year ended December 31, 2025. The Company will discuss its results and 2026 strategic priorities at its Investor Day on March 17, 2026. To our Shareholders: Dear Fellow Shareholders, I am writing to you for the first time as CEO of Bakkt. When I joined the company, it was clear that significant rebuilding was required. Bakkt possessed something rare — a deep regulatory foundation and institutional pedigree rooted in its origins within Intercontinental Exchange — but the company itself had accumulated complexity over time. Strategy had become fragmented, resources were spread across non-core activities, and the...